The European Commission approves the first vaccine for prevention

Reading time:< 1 minute

The European Commission has given its consent for the Imvanex vaccine to be marketed as a medical protection measure against monkeypox, as recommended by the European Medicines Agency (EMA) last week, the manufacturer of this serum, the Danish biotechnology company Bavarian, announced on Monday Nordic, quoted by Reuters and AGERPRES.

The European Commission’s decision to authorize the Imvanex vaccine comes just one day after the World Health Organization (WHO) issued its highest level of alert – a public health emergency of international concern – due to the rapid spread of monkeypox.

“The availability of an authorized vaccine can significantly improve the preparedness of countries to combat emerging diseases, but only through investments and structured plans regarding preparations for biological risk situations,” said Paul Chaplin, CEO of Bavarian Nordic.

This company’s vaccine, the only serum approved to prevent monkeypox infection in the United States and Canada, had until now been licensed in Europe only to combat human smallpox.

But Bavarian Nordic has already supplied several EU countries with doses of its Imvanex vaccine during the current monkeypox epidemic in a procedure known as “off-label use”.

The authorization is valid in all member countries of the European Union, as well as in Iceland, Liechtenstein and Norway, announced the representatives of the Danish company.

The development of the Imvanex vaccine was possible thanks to important investments made by the American administrations in the last two decades.